Development of a fully human T cell engaging bispecific antibody for the treatment of multiple myeloma. Read more about Development of a fully human T cell engaging bispecific antibody for the treatment of multiple myeloma.
Targeted next-generation DNA sequencing of paired tumor and normal DNA to reveal frequent actionable germline alterations. Read more about Targeted next-generation DNA sequencing of paired tumor and normal DNA to reveal frequent actionable germline alterations.
Objective assessment of physical activity during chemotherapy for breast cancer. Read more about Objective assessment of physical activity during chemotherapy for breast cancer.
CyFi: A phase I study exploring the role of cMET pathway inhibition with ficlatuzumab (Fi) combined with high-dose cytarabine (Cy) in patients with high risk relapsed or refractory acute myeloid leukemia (AML). Read more about CyFi: A phase I study exploring the role of cMET pathway inhibition with ficlatuzumab (Fi) combined with high-dose cytarabine (Cy) in patients with high risk relapsed or refractory acute myeloid leukemia (AML).
Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia. Read more about Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.
Breast tumor location in BRCA mutation carriers and implications for prevention. Read more about Breast tumor location in BRCA mutation carriers and implications for prevention.
Improving documentation of surrogate decision makers in medical oncology clinic. Read more about Improving documentation of surrogate decision makers in medical oncology clinic.
Validation of GEMCaP as a DNA based biomarker to predict disease recurrence in patients undergoing prostatectomy for prostate cancer. Read more about Validation of GEMCaP as a DNA based biomarker to predict disease recurrence in patients undergoing prostatectomy for prostate cancer.
Subgroups of survivors with distinct aggravating factors associated with chemotherapy-induced neuropathy (CIN) in the hands. Read more about Subgroups of survivors with distinct aggravating factors associated with chemotherapy-induced neuropathy (CIN) in the hands.
Subgroups of survivors with distinct aggravating factors associated with chemotherapy-induced neuropathy (CIN) in the feet. Read more about Subgroups of survivors with distinct aggravating factors associated with chemotherapy-induced neuropathy (CIN) in the feet.
